Inclusion Criteria:  Diagnosis of chronic rhinosinusitis. Has had a prior bilateral total ethmoidectomy. Has computed tomography (CT) ethmoid cavity opacification. Has a Sinonasal Outcome Test (SNOT-22) ≥ 20 at Screening Visit. Minimum cardinal symptom score. Has been informed of the nature of the study and has provided written informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site or regulatory authority if applicable by national law. Agrees to comply with all study requirements.  Exclusion Criteria:  Ethmoidectomy that was unilateral or partial. Pregnant or breast feeding. Known history of hypersensitivity or intolerance to corticosteroids. History or clinical evidence or suspicion of invasive fungal sinusitis, allergic fungal rhinosinusitis, or atrophic rhinitis. Known history of hypothalamic pituitary adrenal axial dysfunction. Had dental procedure/implant on maxillary dentition within 4 weeks of the Screening visit. Past or present functional vision in only one eye. Past, present, or planned organ transplant or chemotherapy with immunosuppression. With prior cataract surgery or presence (in either eye) of posterior subcapsular cataract of grade 2 or higher, nuclear cataract of grade 3 or higher, or cortical cataract of grade 2 or higher or involving a minimum of center optic zone of 3 mm diameter. Currently participating in an investigational drug or device study.